NCT05764174

Brief Summary

Brief Summary: The main objective of this activity is to assess the effectiveness of different messaging strategies (factual, narrative, mixed and a control) to promote COVID-19 adult vaccination.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,409

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 21, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 17, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 17, 2022

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

January 12, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

March 10, 2023

Completed
Last Updated

March 10, 2023

Status Verified

March 1, 2023

Enrollment Period

3 months

First QC Date

January 12, 2023

Last Update Submit

March 1, 2023

Conditions

Vaccination RefusalCOVID-19

Outcome Measures

Primary Outcomes (1)

  • Percentage point change on the probability of new vaccination for treatment arms vs. control

    The participant reports to have been vaccinated against COVID-19 in the last two weeks

    7 weeks

Secondary Outcomes (3)

  • Percentage point change on the probability of new vaccination conditional on correct answer to the test

    7 weeks

  • Percentage point change on the probability of new vaccination conditional on demographic, socioeconomic and health characteristics

    7 weeks

  • Percentage of attrition between each of the different waves of messages.

    7 weeks

Study Arms (4)

Factual messages

ACTIVE COMPARATOR

Participants in the arm with factual messages will listen to actual data on vaccination.

Behavioral: Factual messages

Narrative message

ACTIVE COMPARATOR

Participants the narrative messages will listen to messages appealing to emotions that were explored in a qualitative study conducted earlier.

Behavioral: Narrative message

Mixed messages

ACTIVE COMPARATOR

The mixed arm will combine both factual and narrative messages.

Behavioral: Mixed message

Control arm

NO INTERVENTION

Participants in the control arm will not be provided with a message and will only be asked for whether they participant got vaccinated in the last two weeks.

Interventions

Factual messagesBEHAVIORAL

Messages with descriptive data on COVID-19 vaccines

Factual messages
Narrative messageBEHAVIORAL

Messages with emotional descriptions on COVID-19 vaccines

Narrative message
Mixed messageBEHAVIORAL

Messages with both descriptive data and emotional descriptions on COVID-19 vaccines

Mixed messages

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Willingness to participate in the trial
  • Being older than 18
  • Have not been fully vaccinated against COVID-19 (those who did not get any vaccine, did not get the complete vaccination scheme or did not get one booster if less than 50 or two boosters if older than 50).

You may not qualify if:

  • Willingness to stop their participation in the trial
  • Being younger than 18
  • Have been fully vaccinated against COVID-19

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Johns Hopkins Bloomberg School of Public Health

Baltimore, Maryland, 21205, United States

Location

MeSH Terms

Conditions

Vaccination RefusalCOVID-19

Condition Hierarchy (Ancestors)

Treatment RefusalTreatment Adherence and ComplianceHealth BehaviorBehaviorPneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Andres Vecino, MD PhD

    Johns Hopkins Bloomberg School of Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Three treatment arms and one control will be deployed.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 12, 2023

First Posted

March 10, 2023

Study Start

September 21, 2022

Primary Completion

December 17, 2022

Study Completion

December 17, 2022

Last Updated

March 10, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

IPD will only be analyzed by the Johns Hopkins team in an anonymized manner. Other researchers will have access only to aggregated information. No attempts to obtain identifiable information will be done and the numbers will be deleted from the main database once completed the data collection

Locations

US(1)